Pulse Biosciences (NASDAQ:PLSE) Trading Up 5.2% – What’s Next?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s share price rose 5.2% on Tuesday . The stock traded as high as $18.52 and last traded at $18.53. Approximately 11,517 shares changed hands during trading, a decline of 90% from the average daily volume of 113,105 shares. The stock had previously closed at $17.61.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

Pulse Biosciences Price Performance

The stock has a 50-day moving average price of $18.23 and a 200-day moving average price of $17.58.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter last year, the business earned ($0.19) earnings per share.

Insider Activity at Pulse Biosciences

In related news, CEO Burke Thomas Barrett sold 50,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at $1,100,456.24. The trade was a 44.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Robert W. Duggan acquired 56,054 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was purchased at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the acquisition, the director now owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 71.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new stake in Pulse Biosciences in the 4th quarter worth about $193,000. Franklin Resources Inc. bought a new stake in shares of Pulse Biosciences in the third quarter valued at approximately $378,000. Barclays PLC grew its position in Pulse Biosciences by 361.4% during the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after buying an additional 23,738 shares in the last quarter. Geode Capital Management LLC increased its stake in Pulse Biosciences by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after acquiring an additional 33,200 shares during the period. Finally, State Street Corp raised its holdings in Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after acquiring an additional 69,696 shares in the last quarter. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.